ipharmacenter Consulting services

Dupixent (dupilumab) has been approved in the European Union as the first targeted therapy in more than a decade for chronic spontaneous urticaria (CSU) in patients 12 years and older whose disease remains uncontrolled on standard antihistamines and who are naïve to anti‑IgE therapy. This decision offers a new first‑line biologic option for an estimated 270,000 adolescents and adults in the EU with CSU inadequately controlled by H1 antihistamines.   Also read: Top 10 pharmace

The U.S. Food and Drug Administration has endorsed Kygevvi (doxecitine and doxribtimine) oral powder, marking the inaugural authorized remedy for thymidine kinase 2 deficiency (TK2d) among grown-ups and young patients showing signs by age 12 or earlier.   Developed by UCB, the drug targets a devastating mitochondrial disorder previously limited to symptom management alone. Grasping TK2d Challenges TK2d represents a scarce inherited condition disrupting mitochondrial DNA produ